Nachrichten zur Ionis Pharmaceuticals Inc. Aktie

Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the…

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 41.07% and 65.19%, respectively, for the quarter ended December 2024. Do…

Ionis Pharmaceuticals beats Q4 estimates, guides 2025 revenue below consensus By Investing.com

Ionis Pharmaceuticals beats Q4 estimates, guides 2025 revenue below consensus…

Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS

Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2024, looking beyond the conventional Wall Street…

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval

…

How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%

The mean of analysts price targets for Ionis Pharmaceuticals (IONS) points to a 55.9% upside in the stock. While this…

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

…

Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story

…

Kiniksa Pharmaceuticals (KNSA) is on the Move, Heres Why the Trend Could be Sustainable

Kiniksa Pharmaceuticals (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that…

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

…

Ionis Pharmaceuticals, Inc. (IONS) Q2 2024 Earnings Call Transcript

…

Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat

…

Kiniksa Pharmaceuticals Q2 2024 Earnings Preview

…

Ionis Pharmaceuticals, Inc. (IONS) HALOS Study of ION582 in Angelman Syndrome - (Transcript)

…

Kiniksa Pharmaceuticals files for $400M mixed shelf

…

Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative

– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis –…

Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript

…

Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape

…

Ionis Pharmaceuticals shares get boost by Oppenheimer, cites strong 2024 By Investing.com

Ionis Pharmaceuticals shares get boost by Oppenheimer, cites strong 2024…

Kyle Jenne returns to Ionis Pharmaceuticals as Executive VP By Investing.com

Kyle Jenne returns to Ionis Pharmaceuticals as Executive VP…

Antisense and RNAi Therapeutics Market Size & Share Envisaged To Reach USD 18.43 Billion By 2032, at 17.8% CAGR Growth: Polaris Market Research

The global Antisense and RNAi Therapeutics Market size and share is currently valued at USD 4.34 billion in 2023. It…

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

…

Ionis Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation

…

Ionis Pharmaceuticals, Inc. (IONS) Q4 2023 Earnings Call Transcript

…

Ionis angioedema drug shows positive results in Phase 3 trial (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) on Monday announced positive topline Phase 3 trial results for its donidalorsen drug candidate for hereditary angioedema…

Kiniksa Pharmaceuticals: Early 2024 Corporate Update A Mixed Bag

…

Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference

HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will…

Ionis Pharmaceuticals: FDA-Zulassung für Wainua zur Behandlung von hATTR-PN

Ionis Pharmaceuticals, eine der größten Beteiligungen im Portfolio von BB Biotech, hat bekannt gegeben, dass die U.S. Food and Drug…

Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment

Ionis Pharmaceuticals and AstraZenecas Wainua has been approved by the U.S. Food and Drug Administration for treating a symptom of…

NASDAQ Composite Index-Titel Ionis Pharmaceuticals-Aktie: So viel Verlust hätte ein Investment in Ionis Pharmaceuticals von vor 3 Jahren eingebracht

Heute vor 3 Jahren fand via Börse NAS wochenend-bedingt kein Handel mit Ionis Pharmaceuticals-Anteilen statt. Den vorherigen Handelstag beendete die…

Ionis Pharmaceuticals: Pioneering Precision Medicine

…

Ionis Pharmaceuticals files to sell ordinary shares

…

Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Heres How

Kiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates.…

Ionis Pharmaceuticals, Inc. (IONS) Q3 2023 Earnings Call Transcript

…

Ionis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

NASDAQ Composite Index-Titel Ionis Pharmaceuticals-Aktie: So viel hätten Anleger mit einem Investment in Ionis Pharmaceuticals von vor einem Jahr verloren

Heute vor 1 Jahr fand via Börse NAS Handel mit Ionis Pharmaceuticals-Anteilen statt. Diesen Tag beendete die Aktie bei 44,83…

Kiniksa Pharmaceuticals Q3 2023 Earnings Preview

…

Ionis Pharmaceuticals vertieft Partnerschaft mit Roche

Ionis Pharmaceuticals, eine Beteiligung von BB Biotech, geht zwei Kooperationen mit Roche ein. Dabei geht es um zwei Frühphasenprogramme zu…

Oligonucleotide API Market revenue to surpass USD 5 Billion by 2035, says Research Nester

Major Oligonucleotide API Market players include Ionis Pharmaceuticals, Inc., Jazz Pharmaceuticals plc, Biogen Inc., Sarepta Therapeutics, Alnylam Pharmaceuticals, Inc., Corden…

Form 8-K IONIS PHARMACEUTICALS For: Aug 21

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates

Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates. The company re-affirms its previously issued financial guidance…

Form 10-Q IONIS PHARMACEUTICALS For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K IONIS PHARMACEUTICALS For: Aug 09

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ionis Pharmaceuticals: Gutes Zahlenwerk wird von der Börse honoriert - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Ionis Pharmaceuticals-Aktienanalyse von "Der Aktionär": Jürgen Dreifürst vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Ionis Pharmaceuticals Inc.…

Ionis Pharmaceuticals (IONS) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2023,…

Ionis Pharmaceuticals: AKTIONÄR-Tipp startet durch – das steckt dahinter

AKTIONÄR-Tipp Ionis Pharmaceuticals hat am Mittwoch ein gutes Zahlenwerk präsentiert. Dieses wird von der Börse dementsprechend honoriert, die Aktie legt…

Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 163.83% and 37.39%, respectively, for the quarter ended June 2023. Do…

Ionis reports second quarter 2023 financial results

Reported Phase 3 data showing eplontersen continued to show improvement in ATTRv-PN through 85 weeks; December 22, 2023 PDUFA date…

Ionis Pharmaceuticals Q2 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…